NIR‐II Imaging‐Guided Mitochondrial‐Targeting Organic Nanoparticles for Multimodal Synergistic Tumor Therapy
Small · 2023
DOI: 10.1002/smll.202207995 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small, 2023. Verfasst von Sha Yang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Center for Molecular Imaging Probe, Hunan Province Key Laboratory of Tumor Cellular and Molecular Pathology, Cancer Research Institute, Hengyang Medi…. Hauptthemen laut MEDLINE: Nanoparticles, Neoplasms, Photochemotherapy. Die Arbeit wurde bisher 53-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Effectively interfering energy metabolism in tumor cells and simultaneously activating the in vivo immune system to perform immune attacks are meaningful for tumor treatment. However, precisely targeted therapy is still a huge challenge. Herein, a mitochondrial‐targeting phototheranostic system, FE‐T nanoparticles (FE‐T NPs) are developed to damage mitochondria in tumor cells and change the tumor immunosuppressive microenvironment. FE‐T NPs are engineered by encapsulating the near‐infrared (NIR) absorbed photosensitizer IR‐FE‐TPP within amphiphilic copolymer DSPE‐SS‐PEG‐COOH for high‐performing with simultaneous mitochondrial‐targeting, near‐infrared II (NIR‐II) fluorescence imaging, and synchronous photothermal therapy (PTT) /photodynamic therapy (PDT) /immune therapy (IMT). In tumor treatment, the disulfide in the copolymer can be cleaved by excess intracellular glutathione (GSH) to release IR‐FE‐TPP and accumulate in mitochondria. After 808 nm irradiation, the mitochondrial localization of FE‐T NPs generated reactive oxygen species (ROS), and hyperthermia, leading to mitochondrial dysfunction, photoinductive apoptosis, and immunogenic cell death (ICD). Notably, in situ enhanced PDT/PTT in vivo via mitochondrial‐targeting with FE‐T NPs boosts highly efficient ICD toward excellent antitumor immune response. FE‐T NPs provide an effective mitochondrial‐targeting phototheranostic nanoplatform for imaging‐guided tumor therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Molecular Imaging Probe, Hunan Province Key Laboratory of Tumor Cellular and Molecular Pathology, Cancer Research Institute, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China.
- Tumor Pathology Research Group & Department of Pathology, Institute of Basic Disease Sciences & School of Basic Medical Sciences, Xiangnan University, Chenzhou, Hunan, 423000, China.
- State Key Laboratory of Supramolecular Structure and Materials, College of Chemistry, Jilin University, Changchun, 130012, China.
- Key Laboratory of Tropical Medicinal Plant Chemistry of Ministry of Education, College of Chemistry and Chemical Engineering, Hainan Normal University, Haikou, Hainan, 571158, China.
ORCID-Profile: Qinglai Yang
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Yang, S., Sun, B., Liu, F., Li, N., Wang, M., Wu, P., Wu, G. L., Fang, H., He, Y., Zhou, W., Xiao, H., Tan, X., Tang, L., Zhu, S., & Yang, Q. (2023). NIR‐II Imaging‐Guided Mitochondrial‐Targeting Organic Nanoparticles for Multimodal Synergistic Tumor Therapy. Small. https://doi.org/10.1002/smll.202207995
Vancouver
Yang S, Sun B, Liu F, Li N, Wang M, Wu P, et al. NIR‐II Imaging‐Guided Mitochondrial‐Targeting Organic Nanoparticles for Multimodal Synergistic Tumor Therapy. Small. 2023. doi:10.1002/smll.202207995
BibTeX
@article{Yang2023,
author = {Yang, Sha and Sun, Bin and Liu, Fen and Li, Na and Wang, Minghui and Wu, Peixian and Wu, Gui-Long and Fang, Huilong and He, Yuxuan and Zhou, Wei and Xiao, Hao and Tan, Xiaofeng and Tang, Li and Zhu, Shoujun and Yang, Qinglai},
title = {NIR‐II Imaging‐Guided Mitochondrial‐Targeting Organic Nanoparticles for Multimodal Synergistic Tumor Therapy},
journal = {Small},
year = {2023},
doi = {10.1002/smll.202207995}
}
EUVIMED